Repligen to Acquire Izon Science for $113M
Ticker: RGEN · Form: 8-K · Filed: Jun 13, 2024 · CIK: 730272
| Field | Detail |
|---|---|
| Company | Repligen Corp (RGEN) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, bioprocessing, extracellular-vesicles
TL;DR
Repligen buying Izon Science for $113M to boost bioprocessing tech.
AI Summary
Repligen Corporation announced on June 13, 2024, that it has entered into a definitive agreement to acquire Izon Science Ltd. for approximately $113 million. This acquisition is expected to enhance Repligen's capabilities in the bioprocessing market, particularly in the area of extracellular vesicles. The transaction is anticipated to close in the third quarter of 2024.
Why It Matters
This acquisition allows Repligen to expand its bioprocessing portfolio with Izon Science's expertise in extracellular vesicles, a growing area in biopharmaceutical research and development.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overvaluation, and failure to achieve expected synergies.
Key Numbers
- $113 million — Acquisition Price (Repligen's purchase of Izon Science Ltd.)
Key Players & Entities
- Repligen Corporation (company) — Acquiring company
- Izon Science Ltd. (company) — Target company
- $113 million (dollar_amount) — Acquisition price
- June 13, 2024 (date) — Announcement date
- third quarter of 2024 (date) — Expected closing period
FAQ
What is the primary strategic rationale behind Repligen's acquisition of Izon Science?
The acquisition is expected to enhance Repligen's capabilities in the bioprocessing market, particularly in the area of extracellular vesicles.
What is the total value of the definitive agreement to acquire Izon Science Ltd.?
The definitive agreement is for approximately $113 million.
When is the acquisition of Izon Science Ltd. expected to close?
The transaction is anticipated to close in the third quarter of 2024.
What specific area of bioprocessing will Izon Science's technology bolster for Repligen?
Izon Science's capabilities in extracellular vesicles will be enhanced.
What is the exact date of the report for this acquisition announcement?
The date of the report is June 13, 2024.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-06-13 07:17:32
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share RGEN The Nasdaq Global Se
Filing Documents
- d126737d8k.htm (8-K) — 23KB
- d126737dex991.htm (EX-99.1) — 11KB
- g126737g0613030111046.jpg (GRAPHIC) — 4KB
- 0001193125-24-160292.txt ( ) — 166KB
- rgen-20240613.xsd (EX-101.SCH) — 3KB
- rgen-20240613_lab.xml (EX-101.LAB) — 18KB
- rgen-20240613_pre.xml (EX-101.PRE) — 11KB
- d126737d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Repligen Corporation on June 13, 2024 (furnished herewith). 104 Cover page from this Current Report on Form 8-K, formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIGEN CORPORATION Dated: June 13, 2024 By: /s/ Tony J. Hunt Tony J. Hunt Chief Executive Officer